Trial Profile
Phase 2 Study of DC-CIK Cells Combined With TACE in the Treatment of Hepatocellular Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dendritic cell activated cytokine-induced killer cells-Shenzhen Hornetcorn (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- Sponsors Shenzhen Hornetcorn Biotechnology
- 03 Jul 2015 New trial record